VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Autodesk, Inc. vs Amgen Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Autodesk, Inc.
ADSK · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Autodesk, Inc.'s moat claims, evidence, and risks.
View ADSK analysisAmgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Amgen Inc. leads (70 / 100 vs 69 / 100 for Autodesk, Inc.).
- Segment focus: Autodesk, Inc. has 5 segments (47.9% in Architecture, Engineering, Construction and Operations (AECO)); Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Autodesk, Inc. has 7 moat types across 2 domains; Amgen Inc. has 5 across 3.
Primary market context
Autodesk, Inc.
Architecture, Engineering, Construction and Operations (AECO)
Architecture, engineering, construction & operations (AECO) software (BIM, civil design, construction management)
Global
B2B / professional
Software vendor (design + construction workflow platform)
47.9%
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Side-by-side metrics
Moat coverage
Shared moat types
Autodesk, Inc. strengths
Amgen Inc. strengths
Segment mix
Autodesk, Inc. segments
Full profile >Architecture, Engineering, Construction and Operations (AECO)
Oligopoly
AutoCAD and AutoCAD LT
Quasi-Monopoly
Manufacturing (MFG)
Oligopoly
Media and Entertainment (M&E)
Competitive
Other (Consulting and other products/services)
Competitive
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.